NCT07771803RecruitingEarly phase 1
A Pilot Study of Soursop Tea in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML) or Multiple Myeloma (MM)
Source: ClinicalTrials.gov · Last updated 18 Aug 2026
Brief summary (registry, in English)
Purpose/Specific Aims The study will determine if there is a reduction in malignant cell burden when patients with relapsed and/or refractory acute myeloid leukemia (AML) or multiple myeloma (MM) consume tea made from the dried leaves of Annona muricata (Soursop). The study goal is to determine the safety and anti-neoplastic efficacy of Annona muricata tea when taken in escalating frequency over a period of 21 days by patients with relapsed/refractory AML or MM for whom there are no standard therapeutic options.
- Status (registry)
- Recruiting
- Phase (registry)
- Early phase 1
- Study type
- Interventional
- Enrollment
- 20 (estimated)
- First submitted
- 10 Jul 2025
- Start date
- 30 Jun 2025
- Primary completion date
- 30 Dec 2026
- Lead sponsor
- Roger Strair
- Diseases
- Multiple myeloma, Acute myeloid leukemia
- NCT number
- NCT07771803
What you commit to
- Study type: Interventional · Early phase 1
- Planned participants: 20
- From 30 Jun 2025 to the primary completion date, 30 Dec 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- Inability to understand the study procedures
- Inability to understand the consent form --Pregnancy, breastfeeding, or inability or unwillingness to use effective contraception
Who the study is looking for
- Patients with relapsed or refractory AML or MM not on any anti-neoplastic therapy who have exhausted all therapies and have no available therapy.
- For AML: Quantifiable leukemia cells in blood (patients without circulating AML blasts may participate if they agree to baseline and post-treatment bone marrow testing)
- For MM: Quantifiable M component (SPEP) or serum free light chain abnormality (ratio greater than 10)
- ECOG PS 0,1, or 2
- ALT, AST less than 3 times ULN
- Bilirubin (total) \< 2.5 mg/dL
- Renal function - estimated GFR \> 40 ml/min
- No uncontrolled/active infections
- Negative pregnancy test if of childbearing potential
- No chronic neurologic disorders (peripheral neuropathy \> grade 2; Parkinson's disease; Alzheimer's disease; other neurologic diseases will be discussed with the PI)
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| MDA at Cooper University Health Care Coordinator of this site? Confirm its status | Camden | United States | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.